Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have ...
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific ...
Panelists discuss how GLP-1 receptor agonists show promising benefits for patients with HFpEF, particularly those with obesity-related disease, through significant weight loss and improved functional ...
Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...
Lexicon Pharmaceuticals received approval for sotagliflozin to treat a broad range of left ventricular ejection fraction, for patients with and without diabetes. The FDA late Friday approved ...
Share on Pinterest Semaglutide drugs like Wegovy may help treat symptoms of heart failure in type 2 diabetes. Image credit: picture alliance/Getty Images. The prevalence of both obesity and type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback